<HTML>
<HEAD>
<TITLE>Page 47</TITLE>
<STYLE TYPE="text/css">
<!--
.pg{position:absolute;top:0px;left:0px;height:1056px;width:816px;}
BODY{font-size:12px;color:rgb(0,0,0);background-color:rgb(255,255,255);}
.ps0{position:absolute;top:1013px;left:690px;height:7px;width:21px;}
.ps1{position:absolute;top:116px;left:67px;height:11px;width:574px;}
.ps2{position:absolute;top:134px;left:67px;height:11px;width:507px;}
.ps3{position:absolute;top:153px;left:67px;height:11px;width:533px;}
.ps4{position:absolute;top:171px;left:67px;height:11px;width:540px;}
.ps5{position:absolute;top:189px;left:67px;height:11px;width:504px;}
.ps6{position:absolute;top:208px;left:67px;height:11px;width:542px;}
.ps7{position:absolute;top:226px;left:67px;height:11px;width:497px;}
.ps8{position:absolute;top:244px;left:67px;height:11px;width:545px;}
.ps9{position:absolute;top:263px;left:67px;height:11px;width:524px;}
.ps10{position:absolute;top:281px;left:67px;height:11px;width:569px;}
.ps11{position:absolute;top:299px;left:67px;height:11px;width:517px;}
.ps12{position:absolute;top:318px;left:67px;height:11px;width:557px;}
.ps13{position:absolute;top:336px;left:67px;height:11px;width:496px;}
.ps14{position:absolute;top:354px;left:67px;height:11px;width:561px;}
.ps15{position:absolute;top:373px;left:67px;height:11px;width:556px;}
.ps16{position:absolute;top:391px;left:67px;height:11px;width:536px;}
.ps17{position:absolute;top:409px;left:67px;height:11px;width:490px;}
.ps18{position:absolute;top:428px;left:67px;height:11px;width:571px;}
.ps19{position:absolute;top:446px;left:67px;height:11px;width:506px;}
.ps20{position:absolute;top:464px;left:67px;height:11px;width:511px;}
.ps21{position:absolute;top:483px;left:67px;height:11px;width:564px;}
.ps22{position:absolute;top:501px;left:67px;height:11px;width:517px;}
.ps23{position:absolute;top:519px;left:67px;height:11px;width:563px;}
.ps24{position:absolute;top:538px;left:67px;height:11px;width:516px;}
.ps25{position:absolute;top:556px;left:67px;height:11px;width:512px;}
.ps26{position:absolute;top:574px;left:67px;height:11px;width:233px;}
.ps27{position:absolute;top:603px;left:67px;height:10px;width:345px;}
.ps28{position:absolute;top:621px;left:67px;height:11px;width:541px;}
.ps29{position:absolute;top:639px;left:67px;height:11px;width:561px;}
.ps30{position:absolute;top:657px;left:67px;height:11px;width:555px;}
.ps31{position:absolute;top:676px;left:67px;height:11px;width:571px;}
.ps32{position:absolute;top:694px;left:67px;height:11px;width:564px;}
.ps33{position:absolute;top:712px;left:67px;height:11px;width:573px;}
.ps34{position:absolute;top:731px;left:67px;height:11px;width:570px;}
.ps35{position:absolute;top:749px;left:67px;height:11px;width:567px;}
.ps36{position:absolute;top:767px;left:67px;height:11px;width:567px;}
.ps37{position:absolute;top:786px;left:67px;height:11px;width:523px;}
.ps38{position:absolute;top:804px;left:67px;height:11px;width:502px;}
.ps39{position:absolute;top:822px;left:67px;height:11px;width:545px;}
.ps40{position:absolute;top:841px;left:67px;height:11px;width:571px;}
.ps41{position:absolute;top:859px;left:67px;height:11px;width:552px;}
.ps42{position:absolute;top:877px;left:67px;height:11px;width:559px;}
.ps43{position:absolute;top:896px;left:67px;height:11px;width:566px;}
.ps44{position:absolute;top:914px;left:67px;height:11px;width:565px;}
.ps45{position:absolute;top:932px;left:67px;height:11px;width:528px;}
.ps46{position:absolute;top:116px;left:410px;height:11px;width:568px;}
.ps47{position:absolute;top:134px;left:410px;height:11px;width:568px;}
.ps48{position:absolute;top:153px;left:410px;height:11px;width:452px;}
.ps49{position:absolute;top:171px;left:410px;height:11px;width:533px;}
.ps50{position:absolute;top:189px;left:410px;height:11px;width:515px;}
.ps51{position:absolute;top:208px;left:410px;height:11px;width:533px;}
.ps52{position:absolute;top:226px;left:410px;height:11px;width:499px;}
.ps53{position:absolute;top:244px;left:410px;height:11px;width:561px;}
.ps54{position:absolute;top:263px;left:410px;height:11px;width:540px;}
.ps55{position:absolute;top:281px;left:410px;height:11px;width:479px;}
.ps56{position:absolute;top:299px;left:410px;height:11px;width:554px;}
.ps57{position:absolute;top:318px;left:410px;height:11px;width:576px;}
.ps58{position:absolute;top:336px;left:410px;height:11px;width:574px;}
.ps59{position:absolute;top:354px;left:410px;height:11px;width:525px;}
.ps60{position:absolute;top:373px;left:410px;height:11px;width:544px;}
.ps61{position:absolute;top:391px;left:410px;height:11px;width:560px;}
.ps62{position:absolute;top:409px;left:410px;height:11px;width:524px;}
.ps63{position:absolute;top:428px;left:410px;height:11px;width:546px;}
.ps64{position:absolute;top:446px;left:410px;height:11px;width:559px;}
.ps65{position:absolute;top:464px;left:410px;height:11px;width:197px;}
.ps66{position:absolute;top:493px;left:410px;height:10px;width:488px;}
.ps67{position:absolute;top:511px;left:410px;height:11px;width:557px;}
.ps68{position:absolute;top:529px;left:410px;height:11px;width:537px;}
.ps69{position:absolute;top:547px;left:410px;height:11px;width:569px;}
.ps70{position:absolute;top:566px;left:410px;height:11px;width:556px;}
.ps71{position:absolute;top:584px;left:410px;height:11px;width:558px;}
.ps72{position:absolute;top:602px;left:410px;height:11px;width:543px;}
.ps73{position:absolute;top:621px;left:410px;height:11px;width:573px;}
.ps74{position:absolute;top:639px;left:410px;height:11px;width:556px;}
.ps75{position:absolute;top:673px;left:410px;height:13px;width:485px;}
.ps76{position:absolute;top:692px;left:410px;height:13px;width:397px;}
.ps77{position:absolute;top:717px;left:410px;height:10px;width:493px;}
.ps78{position:absolute;top:735px;left:410px;height:11px;width:516px;}
.ps79{position:absolute;top:753px;left:410px;height:11px;width:546px;}
.ps80{position:absolute;top:771px;left:410px;height:11px;width:516px;}
.ps81{position:absolute;top:790px;left:410px;height:11px;width:551px;}
.ps82{position:absolute;top:808px;left:410px;height:11px;width:513px;}
.ps83{position:absolute;top:826px;left:410px;height:11px;width:570px;}
.ps84{position:absolute;top:845px;left:410px;height:11px;width:561px;}
.ps85{position:absolute;top:863px;left:410px;height:11px;width:575px;}
.ps86{position:absolute;top:881px;left:410px;height:11px;width:554px;}
.ps87{position:absolute;top:900px;left:410px;height:11px;width:561px;}
.ps88{position:absolute;top:918px;left:410px;height:11px;width:548px;}
.ps89{position:absolute;top:936px;left:410px;height:11px;width:308px;}
.ft0{font-size:8px;font-family:sans-serif;white-space:pre;}
.ft1{font-family:sans-serif;white-space:pre;}
.ft2{font-weight:bold;font-size:11px;font-family:sans-serif;white-space:pre;}
.ft3{font-size:14px;font-family:sans-serif;white-space:pre;}
.ft4{font-weight:bold;font-family:sans-serif;white-space:pre;}
.ft5{font-weight:bold;font-size:13px;font-family:"Times New Roman",Times,serif;white-space:pre;}
.ft6{font-size:11px;font-family:sans-serif;white-space:pre;}
.em0{font-weight:bold;font-family:"Times New Roman",Times,serif;}
.em1{}
.em2{font-weight:normal;font-family:sans-serif;}
.em3{}
-->
</STYLE>
<script language="JavaScript">
<!--
function MM_reloadPage(init) {  //reloads the window if Nav4 resized
  if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
    document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
  else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
MM_reloadPage(true);
// -->
</script>
</HEAD>

<BODY>
<SPAN CLASS="em0" style="left: 0px; top: 0; width: 816px"> 
<p>&nbsp;</p>
</SPAN>
<div id="Layer1" style="position:absolute; width:100px; height:21px; left: 26px; top: 16px"><a href="page46HFandACE.html">To 
  previous page</a></div>
 
<SPAN CLASS="ps0" style="left: 635px; top: 959px"><SPAN CLASS="ft0">47</SPAN></SPAN> 
<SPAN CLASS="ps1" style="top: 50; left: 25px; width: 320"><SPAN CLASS="ft1">and 
minoxidil), weight reduction, and decrease of</SPAN></SPAN> <SPAN CLASS="ps2" style="left: 25px; top: 69; width: 325"><SPAN CLASS="ft1">excessive 
salt intake are capable of reducing</SPAN></SPAN> <SPAN CLASS="ps3" style="width: 325; left: 25px; top: 89"><SPAN CLASS="ft1">increased 
left ventricular mass and wall thick-</SPAN></SPAN> <SPAN CLASS="ps4" style="width: 325; left: 25px; top: 105"><SPAN CLASS="ft1">ness.<SPAN CLASS="em3"><SUP>184<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;In 
one study in men with hyperten-</SPAN></SPAN> <SPAN CLASS="ps5" style="width: 325; left: 25px; top: 126"><SPAN CLASS="ft1">sion, 
treatment with a diuretic and an ACE</SPAN></SPAN> <SPAN CLASS="ps6" style="width: 325; left: 25px; top: 145"><SPAN CLASS="ft1">inhibitor 
was better than treatment with other</SPAN></SPAN> <SPAN CLASS="ps7" style="width: 325; left: 25px; top: 164; height: 11px"><SPAN CLASS="ft1">drug 
classes tested for regressing LVH at 1</SPAN></SPAN> <SPAN CLASS="ps8" style="height: 11px; left: 25px; top: 181; width: 325"><SPAN CLASS="ft1">year.<SPAN CLASS="em3"><SUP>185<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN>&#160;&#160;Observational 
data indicate that the</SPAN></SPAN> <SPAN CLASS="ps9" style="top: 202; left: 25px; width: 325"><SPAN CLASS="ft1">regression 
of electrocardiographic evidence of</SPAN></SPAN> <SPAN CLASS="ps10" style="width: 325; left: 25px; top: 221px"><SPAN CLASS="ft1">LVH 
is associated with a reduction in the risk for</SPAN></SPAN> <SPAN CLASS="ps11" style="width: 325; left: 25px; top: 238"><SPAN CLASS="ft1">cardiovascular 
events.<SPAN CLASS="em3"><SUP>186<SPAN CLASS="em0">F</SPAN></SUP></SPAN>&#160;&#160;However, 
no con-</SPAN></SPAN> <SPAN CLASS="ps12" style="width: 325; left: 25px; top: 259"><SPAN CLASS="ft1">trolled 
studies demonstrate that such reversal of</SPAN></SPAN> <SPAN CLASS="ps13" style="width: 325; left: 25px; top: 278"><SPAN CLASS="ft1">LVH 
offers additional benefits beyond that</SPAN></SPAN> <SPAN CLASS="ps14" style="width: 325; left: 25px; top: 295px"><SPAN CLASS="ft1">offered 
by reduction of blood pressure.<SPAN CLASS="em3"><SUP>187<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;The</SPAN></SPAN> 
<SPAN CLASS="ps15" style="top: 316px; left: 25px; width: 325"><SPAN CLASS="ft1">electrocardiogram 
remains valuable not only for</SPAN></SPAN> <SPAN CLASS="ps16" style="width: 325; left: 25px; top: 335"><SPAN CLASS="ft1">detecting 
left atrial hypertrophy and LVH but</SPAN></SPAN> <SPAN CLASS="ps17" style="width: 325px; left: 25px; top: 354px"><SPAN CLASS="ft1">also 
for identifying evidence of myocardial</SPAN></SPAN> <SPAN CLASS="ps18" style="width: 325; left: 25px; top: 371"><SPAN CLASS="ft1">ischemia 
and arrhythmia.<SPAN CLASS="em3"><SUP>188<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;Echocardiography</SPAN></SPAN> 
<SPAN CLASS="ps19" style="top: 392px; left: 25px; width: 325"><SPAN CLASS="ft1">is 
more sensitive and specific for identifying</SPAN></SPAN> <SPAN CLASS="ps20" style="width: 325; left: 25px; top: 411"><SPAN CLASS="ft1">LVH, 
but it is too expensive for routine use.</SPAN></SPAN> <SPAN CLASS="ps21" style="width: 325; left: 25px; top: 430px"><SPAN CLASS="ft1">Limited 
echocardiography will identify LVH at a</SPAN></SPAN> <SPAN CLASS="ps22" style="width: 325; left: 25px; top: 449"><SPAN CLASS="ft1">cost 
that may justify its use in some patients</SPAN></SPAN> <SPAN CLASS="ps23" style="width: 325; left: 25px; top: 468px"><SPAN CLASS="ft1">(e.g., 
those with untreated stage 1 hypertension,</SPAN></SPAN> <SPAN CLASS="ps24" style="width: 325; left: 25px; top: 487"><SPAN CLASS="ft1">no 
cardiovascular risk factors, no evidence of</SPAN></SPAN> <SPAN CLASS="ps25" style="width: 325; left: 25px; top: 506"><SPAN CLASS="ft1">clinical 
cardiovascular disease, and no target</SPAN></SPAN> <SPAN CLASS="ps26" style="width: 233px; left: 25px; top: 523"><SPAN CLASS="ft1">organ 
damage).<SPAN CLASS="em3"><SUP>189<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps27" style="width: 345px; left: 25px; top: 554"><SPAN CLASS="ft2">Patients 
With Cardiac Failure</SPAN></SPAN> <SPAN CLASS="ps28" style="top: 573px; left: 25px; width: 325px"><span class="ft1">In 
patients with hypertension, structural alter-</span></SPAN> <SPAN CLASS="ps29" style="width: 325; left: 25px; top: 592"><span class="ft1">ations 
in the left ventricle (LVH or left ventricu-</span></SPAN> <SPAN CLASS="ps30" style="width: 325; left: 25px; top: 611"><span class="ft1">lar 
remondeling with dilation) as well as myocar-</span></SPAN> <SPAN CLASS="ps31" style="width: 325; left: 25px; top: 630"><SPAN CLASS="ft1"> 
dial ischemia from coronary artery atherosclerosis</SPAN></SPAN> <SPAN CLASS="ps32" style="width: 325; left: 25px; top: 649"><SPAN CLASS="ft1">may 
contribute to the development of heart fail-</SPAN></SPAN> <SPAN CLASS="ps33" style="width: 325; left: 25px; top: 668"><SPAN CLASS="ft1">ure. 
&#160;Some patients with hypertension (current or</SPAN></SPAN> <SPAN CLASS="ps34" style="width: 325; left: 25px; top: 687"><SPAN CLASS="ft1">past) 
develop heart failure with a normal ejection</SPAN></SPAN> <SPAN CLASS="ps35" style="width: 325; left: 25px; top: 706"><SPAN CLASS="ft1">fraction, 
implying diastolic dysfunction. &#160;Reports</SPAN></SPAN> <SPAN CLASS="ps36" style="width: 325; left: 25px; top: 725"><SPAN CLASS="ft1">from 
the Framingham Heart Study have demon-</SPAN></SPAN> <SPAN CLASS="ps37" style="width: 325; left: 25px; top: 744px"><SPAN CLASS="ft1">strated 
that hypertension continues to be the</SPAN></SPAN> <SPAN CLASS="ps38" style="top: 763; left: 25px; width: 325"><SPAN CLASS="ft1">major 
cause of left ventricular failure in the</SPAN></SPAN> <SPAN CLASS="ps39" style="width: 325; left: 25px; top: 780"><SPAN CLASS="ft1">United 
States.<SPAN CLASS="em3"><SUP>190<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;Control 
of elevated arterial</SPAN></SPAN> <SPAN CLASS="ps40" style="top: 801; left: 25px; width: 325"><SPAN CLASS="ft1">pressure 
using lifestyle changes and drug therapy</SPAN></SPAN> <SPAN CLASS="ps41" style="width: 325; left: 25px; top: 820"><SPAN CLASS="ft1">improves 
myocardial function and prevents and</SPAN></SPAN> <SPAN CLASS="ps42" style="width: 325; left: 25px; top: 839"><SPAN CLASS="ft1">reduces 
heart failure and cardiovascular mortali-</SPAN></SPAN> <SPAN CLASS="ps43" style="width: 325; left: 25px; top: 856"><SPAN CLASS="ft1">ty.<SPAN CLASS="em3"><SUP>119<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;After 
myocardial infarction, therapy with</SPAN></SPAN> <SPAN CLASS="ps44" style="top: 877px; left: 25px; width: 325"><SPAN CLASS="ft1">ACE 
inhibitors prevents subsequent heart failure</SPAN></SPAN> <SPAN CLASS="ps45" style="top: 894; width: 325px; left: 25px"><SPAN CLASS="ft1">and 
reduces morbidity and mortality.<SPAN CLASS="em3"><SUP>191<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN>&#160;&#160;<font color="#FF0000">In</font></SPAN></SPAN> 
<SPAN CLASS="ps46" style="width: 300; left: 369px; top: 50"><SPAN CLASS="ft1"><font color="#FF0000">treating 
heart failure, ACE inhibitors, when used</font></SPAN></SPAN> <SPAN CLASS="ps47" style="width: 300px; top: 69px; left: 369"><SPAN CLASS="ft1"><font color="#FF0000">alone 
or in conjunction with digoxin or diuretics,</font></SPAN></SPAN> <SPAN CLASS="ps48" style="top: 88px; left: 369px; width: 300"><SPAN CLASS="ft1"><font color="#FF0000">are 
effective in reducing morbidity and</font></SPAN></SPAN> <SPAN CLASS="ps49" style="top: 105; left: 369px; width: 300"><SPAN CLASS="ft1"><font color="#FF0000">mortality.<SPAN CLASS="em3"><SUP>192<SPAN CLASS="em0">M</SPAN></SUP></SPAN>&#160;</font>&#160;When 
ACE inhibitors are con-</SPAN></SPAN> <SPAN CLASS="ps50" style="width: 300; left: 369px; top: 126"><SPAN CLASS="ft1">traindicated 
or not tolerated, the vasodilator</SPAN></SPAN> <SPAN CLASS="ps51" style="width: 300; left: 369px; top: 145"><SPAN CLASS="ft1">combination 
of hydralazine hydrochloride and</SPAN></SPAN> <SPAN CLASS="ps52" style="width: 300; left: 369px; top: 164px"><SPAN CLASS="ft1">isosorbide 
dinitrate is also effective in these</SPAN></SPAN> <SPAN CLASS="ps53" style="width: 300; left: 369px; top: 181"><SPAN CLASS="ft1">patients.<SPAN CLASS="em3"><SUP>193<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN>&#160;&#160;The 
alpha-beta-blocker carvedilol</SPAN></SPAN> <SPAN CLASS="ps54" style="top: 202; left: 369px; width: 300"><SPAN CLASS="ft1">added 
to ACE inhibitors has been shown to be</SPAN></SPAN> <SPAN CLASS="ps55" style="width: 300; left: 369px; top: 219"><SPAN CLASS="ft1">beneficial,<SPAN CLASS="em3"><SUP>194<SPAN CLASS="em0">Ra,</SPAN>195<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN>&#160;and, 
in one trial, the</SPAN></SPAN> <SPAN CLASS="ps56" style="width: 300; left: 369px; top: 240"><SPAN CLASS="ft1">angiotensin 
II receptor blocker losartan potassi-</SPAN></SPAN> <SPAN CLASS="ps57" style="width: 300; left: 369px; top: 259"><SPAN CLASS="ft1">um 
was superior to captopril in reducing mortali-</SPAN></SPAN> <SPAN CLASS="ps58" style="width: 300; left: 369px; top: 276"><SPAN CLASS="ft1">ty.<SPAN CLASS="em3"><SUP>196<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN>&#160;&#160;The 
dihydropyridine calcium antagonists</SPAN></SPAN> <SPAN CLASS="ps59" style="top: 297; left: 369px; width: 300"><SPAN CLASS="ft1">amlodipine 
besylate and felodipine have been</SPAN></SPAN> <SPAN CLASS="ps60" style="width: 300; left: 369px; top: 316px"><SPAN CLASS="ft1">demonstrated 
to be safe in treating angina and</SPAN></SPAN> <SPAN CLASS="ps61" style="top: 335; left: 369px; width: 300"><SPAN CLASS="ft1">hypertension 
in patients with advanced left ven-</SPAN></SPAN> <SPAN CLASS="ps62" style="width: 300; left: 369px; top: 354"><SPAN CLASS="ft1">tricular 
dysfunction when used in addition to</SPAN></SPAN> <SPAN CLASS="ps63" style="width: 300; left: 369px; top: 371"><SPAN CLASS="ft1">ACE 
inhibitors, diuretics, or digoxin;<SPAN CLASS="em3"><SUP>197<SPAN CLASS="em0">Ra</SPAN>,198<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps64" style="width: 300; left: 369px; top: 392"><SPAN CLASS="ft1">other 
calcium antagonists are not recommended</SPAN></SPAN> <SPAN CLASS="ps65" style="width: 197px; left: 369px; top: 411"><SPAN CLASS="ft1">in 
these patients.</SPAN></SPAN> <SPAN CLASS="ps66" style="top: 440; left: 369; width: 300"><SPAN CLASS="ft2">Patients 
With Peripheral Arterial Disease</SPAN></SPAN> <SPAN CLASS="ps67" style="top: 459; left: 369px; width: 300"><SPAN CLASS="ft1">Hypertension 
is one of the major risk factors for</SPAN></SPAN> <SPAN CLASS="ps68" style="width: 300; left: 369px; top: 478"><SPAN CLASS="ft1">the 
development of carotid atherosclerosis and</SPAN></SPAN> <SPAN CLASS="ps69" style="width: 300; left: 369px; top: 497px"><SPAN CLASS="ft1">peripheral 
arterial disease with intermittent clau-</SPAN></SPAN> <SPAN CLASS="ps70" style="width: 300; left: 369px; top: 516"><SPAN CLASS="ft1">dication 
and aneurysms. &#160;However, data are not</SPAN></SPAN> <SPAN CLASS="ps71" style="width: 300; left: 369px; top: 535px"><SPAN CLASS="ft1">available 
to determine whether antihypertensive</SPAN></SPAN> <SPAN CLASS="ps72" style="width: 300; left: 369px; top: 554"><SPAN CLASS="ft1">therapy 
will alter the course of these processes.</SPAN></SPAN> <SPAN CLASS="ps73" style="width: 300; left: 369px; top: 573"><SPAN CLASS="ft1">Early 
multicenter trials demonstrated a reduction</SPAN></SPAN> <SPAN CLASS="ps74" style="width: 300; left: 369px; top: 590"><SPAN CLASS="ft1">in 
deaths from dissecting aortic aneurysms.<SPAN CLASS="em3"><SUP>199<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps75" style="top: 621; left: 369px; width: 300"><SPAN CLASS="ft4">P<SPAN CLASS="em1">ATIENTS</SPAN>&#160;W<SPAN CLASS="em1">ITH</SPAN>&#160;H<SPAN CLASS="em1">YPERTENSION</SPAN><SPAN CLASS="em1"> 
</SPAN>&#160;<SPAN CLASS="em1">AND</SPAN></SPAN></SPAN> <SPAN CLASS="ps76" style="width: 300; left: 369px; top: 640"><SPAN CLASS="ft4">O<SPAN CLASS="em1">THER</SPAN>&#160;C<SPAN CLASS="em1">OEXISTING</SPAN>&#160;D<SPAN CLASS="em1">ISEASES</SPAN></SPAN></SPAN> 
<SPAN CLASS="ps77" style="width: 300; left: 369px; top: 669"><SPAN CLASS="ft2">Patients 
With Renal Parenchymal Disease</SPAN></SPAN> <SPAN CLASS="ps78" style="width: 300; left: 369px; top: 688"><SPAN CLASS="ft5">Pathophysiology. 
&#160;<SPAN CLASS="em2">Hypertension</SPAN><SPAN CLASS="em2"> </SPAN><SPAN CLASS="em2">may</SPAN><SPAN CLASS="em2"> 
</SPAN><SPAN CLASS="em2">result</SPAN></SPAN></SPAN> <SPAN CLASS="ps79" style="width: 300; left: 369px; top: 707"><SPAN CLASS="ft1">from 
any form of renal disease that reduces the</SPAN></SPAN> <SPAN CLASS="ps80" style="width: 300; left: 369px; top: 726"><SPAN CLASS="ft1">number 
of functioning nephrons, leading to </SPAN></SPAN> <SPAN CLASS="ps81" style="width: 300; left: 369px; top: 743"><SPAN CLASS="ft1">sodium 
and water retention.<SPAN CLASS="em3"><SUP>200<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;Hypertensive</SPAN></SPAN> 
<SPAN CLASS="ps82" style="top: 764px; left: 369px; width: 300"><SPAN CLASS="ft1">nephrosclerosis 
is among the most common </SPAN></SPAN> <SPAN CLASS="ps83" style="width: 300; left: 369px; top: 783"><SPAN CLASS="ft1">causes 
of progressive renal disease, particularly in</SPAN></SPAN> <SPAN CLASS="ps84" style="width: 300; left: 369px; top: 800"><SPAN CLASS="ft1">African 
Americans.<SPAN CLASS="em3"><SUP>201<SPAN CLASS="em0">X</SPAN></SUP></SPAN>&#160;&#160;Followup 
of large num-</SPAN></SPAN> <SPAN CLASS="ps85" style="top: 821; left: 369px; width: 300"><SPAN CLASS="ft1">bers 
of men screened for the Multiple Risk Factor</SPAN></SPAN> <SPAN CLASS="ps86" style="width: 300; left: 369px; top: 840"><SPAN CLASS="ft1">Intervention 
Trial and of male veterans has pro-</SPAN></SPAN> <SPAN CLASS="ps87" style="width: 300; left: 369px; top: 859"><SPAN CLASS="ft1">vided 
the most conclusive and direct evidence of</SPAN></SPAN> <SPAN CLASS="ps88" style="width: 300; left: 369px; top: 878"><SPAN CLASS="ft1">a 
relationship between blood pressure and end-</SPAN></SPAN> <SPAN CLASS="ps89" style="top: 895; left: 369px; width: 300"><span class="ft1">stage 
renal disease</span><SPAN CLASS="ft6">.<SPAN CLASS="em3"><SUP>202<SPAN CLASS="em0">F,</SPAN>203<SPAN CLASS="em0">F</SPAN></SUP></SPAN></SPAN></SPAN> 
</BODY>

</HTML>
